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Abstract 
The emergence of highly pathogenic avian influenza A virus (HPAIV) subtype H5N1 in 1997 has since 
resulted in large outbreaks in poultry and in transmission from poultry to humans, mostly in southeast 
Asia, but also in several European countries. Effective diagnosis and control measures are essential 
for the management of HPAIV infections. To develop a rapid diagnostic test, a panel of murine 
monoclonal antibodies (mAbs) against influenza virus A subtype H5 was generated. Eleven mAbs 
were produced and characterised according to their reactivity by indirect and sandwich ELISA and 
western blotting against different H5 subtypes representing past and viruses currently circulating. Ten 
out of 11 mAbs reacted strongly with the haemagglutinin (HA) protein of H5 viruses, whereas one mAb 
reacted with the M1 protein. Targeted HA protein epitopes seemed to be conformational. One 
hybridoma clone binds to a linear epitope of the M1 protein. One specific mAb reacts with HPAIV H5 in 
the immunofluorescence test, and two antibodies neutralised H5 viruses. On the basis of the results, 
the set of seven mAbs is appropriate for developing diagnostic tests. With the generated mAbs, a 
sandwich ELISA was developed recognising all H5N1 strains tested but no other influenza viruses. 
With this ELISA, as little as 0.005 HA units or 0.1 ng/ml H5N1 was detected, surpassing other ELISA 




Influenza virus A, subtype H5N1 infects birds and has been thought to have limited zoonotic potential 
and public health significance. In 1997, with the emergence and spread of the new Asian lineage 
H5N1 virus, this assumption has changed dramatically, as this virus is able to infect a broad spectrum 
of non-avian species, including humans (Capua and Alexander, 2007). Viruses of the genus influenza 
A in the family of Orthomyxoviridae are grouped into 16 haemagglutinin (HA) subtypes (H1–16) 
according to their reactivity in serological tests (haemagglutination inhibition test) and into nine 
neuraminidase (NA) subtypes (N1–9). The eight single-stranded RNA segments of the influenza A 
virus genome encode 11 viral proteins. According to their virulence, avian influenza viruses are 
categorised into two groups: highly pathogenic avian influenza viruses (HPAIV), which cause high 
mortality approaching 100% in chickens, and low pathogenic avian influenza viruses (LPAIV), which 
cause mild respiratory diseases in poultry ( [Deregt et al., 2006] and [Alexander, 2007]). Infection with 
HPAIV, generally caused by strains of subtypes H5 and H7, results in high economic losses in the 
poultry industry. Retrospective studies have shown that domestic poultry plays a substantial role in 
generating novel influenza A virus strains with the capacity to cross the species barrier ( [Capua and 
Alexander, 2007] and [Yang et al., 2008]). The recent HPAIV H5N1 virus has been transmitted 
occasionally from fowl to human, and a few human-to-human transmissions (family clusters) have 
been reported. Until August 2010, 505 human cases were laboratory confirmed, 300 of which (59%) 
had a fatal outcome (WHO, 2010). 
Laboratory diagnosis of influenza is essential for surveillance, treatment and vaccine development 
(Petric et al., 2006). The diagnosis of HPAIV H5 generally includes conventional virus culture followed 
by serological differentiation but also may include rapid and more cost-effective technologies that allow 
for the detection of subtype-specific viral antigens or nucleic acids. For the diagnosis of HPAIV H5 
  
infections in humans, the WHO recommended RT-PCR, real-time RT-PCR or other molecular 
methods, such as rapid antigen detection systems or so-called point-of-care testing and virus culture 
(WHO, 2007). Commercially available rapid antigen detection systems can, in principle, be used at the 
point of care, even by untrained personnel without laboratory equipment, and provide results within 
15–30 min. However, point-of-care tests (generally lateral flow tests) vary greatly in their sensitivity 
and specificity, and laboratory confirmation of reactive samples is required ( [Beigel et al., 2005], 
[Petric et al., 2006], [Chan et al., 2007] and [Cui and Tong, 2008]). Direct comparison of the sensitivity 
and specificity of the available point-of-care tests is difficult due to variable conditions for test 
evaluations. Preliminary results showed a poor clinical sensitivity by commercial rapid antigen 
detection systems for the diagnosis of avian influenza (AI) in patients. Furthermore, some of the tests 
detect several subtypes of influenza A viruses and are therefore not H5-specific ( [Chotpitayasunondh 
et al., 2005], [Chan et al., 2007] and [Ghebremedhin et al., 2009]). It has been suggested that these 
tests should be used only in situations with a high risk of avian influenza and when high viral loads are 
expected, and lateral flow ELISA tests are not recommended for surveillance programs (Charlton et 
al., 2009). 
However, there is a need for specific and sensitive rapid antigen detection systems. Monoclonal 
antibodies (mAbs), as compared to polyclonal antibodies (pAbs), are able to increase the specificity 
and sensitivity of immunological assay systems (Yang et al., 2008) and are important for the selective 
detection of H5N1 viruses, antibody testing, and vaccine efficacy studies and might be of possible 
therapeutic use ( [Du et al., 2009] and [Oh et al., 2009]). In this study, newly developed murine mAbs 
against influenza virus A, subtype H5, were analysed for their reactivity in immunochemical test 
systems, their ability to neutralise influenza virus A, subtype H5N1, and their suitability as tools for the 
development of improved point-of-care tests. 
 
2. Materials and methods 
2.1. Cells and antigens 
MDCK cells were propagated in Eagle's minimal essential medium (EMEM; Invitrogen, Paisly, UK) 
supplemented with 10% foetal bovine serum (FBS, PAN, Aidenbach, Germany), 1% glutamine (PAA, 
Pasching, Austria), and 1% non-essential amino acids (PAA). 
Thirty influenza A viruses, representing all 16 HA subtypes, including 11 H5 isolates with 
representatives of clades 1 and 2.2, and two isolates of influenza B virus (Table 1) were grown either 
in 10-day-old embryonated chicken eggs (specific pathogen-free SPF eggs; Lohmann Tierzucht, 
Cuxhaven, Germany) or in MDCK cells. Stocks from H1N1, H3N2, H5N2, H5N6, and all H5N1 
isolates, H7N1, and influenza B viruses were produced on MDCK monolayers, whereas subtypes H2, 
H5, and H7-H16 were propagated in embryonated eggs. The virus was harvested either from allantoic 
fluid or cell supernatant. For the latter, the cells were scratched and centrifuged with the cell 
supernatant at 4,500 × g (Multifuge 3 S-R, Thermo Fisher Scientific, Langenselbold, Germany) for 
10 min at room temperature. The supernatant or the allantoic fluid was collected, inactivated with beta-
propiolactone (Ferak Berlin, Berlin, Germany), and stored at −80 °C. Inactivation was performed with 
an ice-cold dilution of beta-propiolactone (1:10 in Tris-HCl, pH 8.0). The virus material was mixed 
thoroughly with beta-propiolactone. The pH of the mix was adjusted to a value between 7.4 and 8.4. 
The solution was stored at 4 °C overnight, followed by incubation at 37 °C for 2 h. Inactivation was 
verified by infection of cells or eggs. Neither cytopathic effects in cell culture nor HA activity in the 
allantoic fluid or supernatant were observed after four passages. Furthermore, an H5N1-specific 
TaqMan-PCR was negative in such samples, proving the inactivation of virus. Only inactivated viruses 
were used for ELISA, western blot, and for the immunisation of mice under bio-safety level (BSL)-2 
conditions. Virus quantitation of infectious materials was performed by HA assay (egg-grown virus) or 
by plaque tests on MDCK cells. In the case of infectious HPAIV H5, virus propagation and 
experiments were performed in a BSL 3 laboratory. The specific reaction of the generated mAbs was 
further tested with 16 different respiratory viruses, 10 enteroviruses (Table 1), and 16 bacteria causing 






2.2. Antigen preparation 
Virus from allantoic fluid or from cell culture supernatant was inactivated and then concentrated by 
ultracentrifugation at 70,000 × g for 2 h at 4 °C through a 30% sucrose cushion. The virus pellet was 
resuspended in PBS, and aliquots were stored at −80 °C. One aliquot was used for determining the 
protein concentration by a BCA-protein assay (Thermo Fisher Scientific, Schwerte, Germany). 
 
2.3. Control sera 
Polyclonal rabbit anti-AIV H5N1 serum was produced by the immunisation of a rabbit with inactivated 
H5N1 (A/Whooper Swan/Germany; R65-2/06). Polyclonal mouse sera were collected from the mice 
immunised for hybridoma generation. Pre-immunisation sera served as negative controls. 
 
2.4. Generation of monoclonal antibodies against avian influenza virus subtype H5 
Female BALB/c and C57BL/6 mice, 8–9 weeks old, were immunised intraperitoneally with 17 μg of 
H5N1 A/Whooper Swan/Germany (R65-2/06) mixed with an equal volume of complete Freund's 
adjuvant (Sigma–Aldrich Chemie, Steinheim, Germany), followed by a booster immunisation four 
weeks later of the same dose mixed with incomplete Freund's adjuvant (Sigma–Aldrich). The mice 
received three boosts of the same amount of antigen in PBS on days −3, −2, and −1 prior to fusion. 
The spleens were excised and the splenocytes were fused with myeloma cells (P3X63Ag8.653) 
according to the previously described protocol ( [Dorner et al., 2003] and [Pauly et al., 2009]). 
Beginning on day 10 after fusion, hybridoma supernatants were screened for specific antibodies. 
 
2.5. Screening of supernatants for the production of antibodies 
A three-step approach was used: initial screening of hybridoma supernatants was performed by 
indirect ELISA, followed by selection of antibody-producing hybridoma cells by cell-ELISA and 
sandwich assay. MAbs were purified using a HiTrap Protein G HP column (GE Healthcare, Munich, 
Germany) and subsequently dialysed in PBS overnight. After dialysis, the protein concentration was 
determined using a NanoPhotometer™ UV/Vis spectrophotometer (Implen, Munich, Germany). If 
values were lower than 1 mg/ml, antibodies were concentrated by means of the centrifugal filter device 
Amicon
®
 Ultra-4 (Millipore Corp., Bedford, USA). 
Isotyping of purified mAbs was performed with the IsoStrip Mouse Monoclonal Antibody Isotyping Kit 
(Roche-Applied Sciences, Mannheim, Germany). 
For specificity and sensitivity testing of purified mAbs and for the definition of optimal antibody pairs, 
indirect ELISA and sandwich ELISA were used. 
 
2.6. Indirect ELISA 
Nunc Maxisorb
®
 microtitre plates (VWR International, Darmstadt, Germany) were coated overnight at 
4 °C with viral antigens (1 μg/ml in PBS) or, as negative controls, with BSA, ovalbumin, or allantoic 
fluid (50 μl each per well). After blocking (blocking buffer: 2% skimmed milk in PBS containing 0.1% 
Tween 20 [PBS-T]), 50 μl of hybridoma culture supernatants or purified mAbs (1 μg/ml in blocking 
buffer) were added, and the plates were incubated for 1 h at room temperature (RT). Each well was 
then incubated for 30 min at RT with 50 μl peroxidase-conjugated, Fcγ-specific goat anti-mouse IgG 
(Dianova, Hamburg, Germany) diluted 1:2000 in blocking buffer. PBS-T washes were performed three 
times in between incubations and six times before adding substrate, using an automated plate washer 
(Tecan, Crailsheim, Germany). The binding of antibodies was determined by 15 min of incubation with 
100 μl/well 3,3′,5,5′-tetramethylbenzidine substrate (TMB dihydrochloride tablets; Sigma-Aldrich) 
according to the manufacturer's instructions. The reaction was stopped by adding 100 μl of 1 M 
H2SO4. The absorbance (A) was measured at 450/620 nm using an automated plate reader (Tecan). 
  
Unspecific cross-reactivity to bacterial antigens were only tested by indirect ELISA using 1 × 10
6
 cfu/ml 
in 0.1 M NaHCO3, 50 μl per well. 
2.7. Cell-ELISA 
The cell-ELISA was used as a confirmation assay for the detection of influenza virus-specific 
hybridoma cell supernatants, as this assay permits the differentiation of reactions of antibodies with 
influenza A virus and cellular antigens. The test was performed essentially as described previously 
(Pauli et al., 1984). Briefly, MDCK cells were cultivated on 96-well plates until they reached 100% 
confluence, infected with 100 μl of H5N1 virus (1 × 10
3
 PFU/ml, A/Whooper Swan/Germany [R65-
2/06]), and incubated for 24 h at 37 °C with 5% CO2. After fixing with 3% formaldehyde in PBS, 50 μl 
of hybridoma cell supernatant was added, and the plates were incubated for 30 min at 37 °C in a 
humid chamber. After washing five times with PBS, the plates were incubated with 50 μl of HRP-
conjugated goat anti-mouse IgG (Thermo Fisher Scientific) as described. Finally, 50 μl of the freshly 
prepared substrate solution (10 mg 3-amino-9-ethyl-carbazole [Sigma-Aldrich Chemie] dissolved in 
3 ml dimethylsulphoxide added to 50 ml of 20 mM sodium acetate buffer [pH 5.0–5.5] and 400 μl 3% 
H2O2) was added to each well of the plates. The reaction was stopped after 30 min by washing with 
tap water and was then analysed by light microscopy. 
 
2.8. Sandwich ELISA 
The sandwich assay was used to (a) evaluate the ability of the mAbs to function as a detector or to 
capture antibodies in a rapid antigen detection system (antigen capture assay) and to (b) determine 
the detection limit of selected mAb pairs. For (a), 96-well plates were coated with 50 μl of appropriately 
diluted anti-H5 polyclonal rabbit antibody (1:1000) and incubated overnight at 4 °C. Coated wells were 
incubated with the antigen solution (1 μg/ml in PBS, 50 μl/well) for 2 h at RT. MAbs were biotinylated, 
diluted in blocking buffer according to ELISA pre-testings, and incubated with the immobilised virus for 
1 h at RT. Finally, HRP-conjugated streptavidin 1:2000 in blocking buffer (Dianova) was added to each 
well and was further processed as described for the indirect ELISA. To examine the ability of mAbs to 
capture H5 antigen, the wells were coated with mAbs (1 μg/ml; capture antibody), and anti-H5 
polyclonal rabbit antibodies (1:1000) were used as detector antibodies. Bound rabbit antibodies were 
detected by HRP-conjugated goat anti-rabbit IgG, 1:2500 (Dianova). For (b), capture mAbs were 
diluted to 0.5, 1.0, and 5.0 μg/ml. Antigen (H5N1 A/Whooper Swan/Germany [R65-2/06]) was applied 
in serial dilutions from 0.1 ng/ml to 10 μg/ml. Appropriately diluted biotinylated mAbs were used as 
detector antibodies. Binding of biotinylated antibodies was determined either via peroxidase-
conjugated streptavidin (SA-POD) or, for increased sensitivity, with PolyHRP40-conjugated 
streptavidin (Senova Immunoassay Systems, Jena, Germany) and processed further as described 
above. 
 
2.9. Western blot 
Virus preparations of inactivated subtype H5 viruses (see Table 1) or H1N1 virus (A/New 
Caledonia/20/99) in Laemmli buffer (Laemmli, 1970) with or without 2-mercaptoethanol were boiled for 
5 min before loading. Samples were separated by a 10% or 12.5% SDS-polyacrylamide gel under 
reducing or non-reducing conditions and transferred onto polyvinylidene fluoride (PVDF) membranes 
(Bio-Rad Laboratories, Munich, Germany). The membrane was submerged in blocking buffer for at 
least 30 min, incubated with the purified mAbs (1:2000 dilution in blocking buffer) for 1 h at RT, 
washed extensively with PBS-T, and bound antibodies were detected by incubation (30 min, RT) with 
horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (H + L) (Thermo Fisher Scientific; 
diluted 1:20,000 in blocking buffer). Finally, the antibody-binding was visualised using the Immun-




To confirm the binding reaction of mAbs to the influenza virus HA protein, viral H5 glycoproteins were 
N-deglycosylated with PNGase F (New England Biolabs Inc., Frankfurt/Main, Germany), based on the 
  
manufacturer's instructions and the protocol of Wagner et al. (2000). Briefly, a 10 μl sample, 
containing 680 ng of inactivated H5N1 virus and 1 μl of denaturing buffer, was combined with 500 U of 
PNGase F in G7 buffer and 1% Nonidet P-40 to a final reaction volume of 20 μl and was incubated for 
6 h at 37 °C, without a denaturation step at 100 °C prior to enzyme treatment. Controls were treated 
similarly in the absence of PNGase F. The deglycosylation reaction of the HA proteins was analysed 
by western blotting under non-reducing conditions as described above, with mAb 492/3/E6 as the 
primary antibody and the polyclonal serum of the immunised mouse as a positive control. 
 
2.11. Immunofluorescence staining of cells infected with H5N1 virus 
H5N1 (A/Whooper Swan/Germany [R65-2/06])-infected MDCK cells and mock-infected cells were 
mixed and incubated on microscope slides with reaction wells for 6 h. The incubation time of 6 h was 
selected after prior experiments with different incubation times. Then, the slides were fixed in 3% 
formaldehyde in PBS and stored in 1.5% formaldehyde at 4 °C until use. For immunofluorescence 
staining, slides were incubated in 0.1% TritonX-100. The purified mAbs were titrated in serial dilutions 
from 100 to 0.1 μg/ml in sample buffer (PBS with 0.2% sodium azide and 2% BSA). After a washing 
step, slides were incubated with FITC-conjugated goat anti-mouse secondary antibody (Dianova) in a 
final dilution of 1:160. After washing, the slides were covered with mounting medium and were 
investigated under a fluorescence microscope (EURO Star II, Euroimmun, Lübeck, Germany). As 
controls, immunofluorescence assays were similarly performed with H1N1- and H3N2-infected cells. 
 
2.12. Microtitre neutralisation assay 
A microtitre neutralisation (MN) assay was used to test the neutralising capacity of the mAbs. First, 
mAbs were serially diluted from 100 μg/ml to 0.1 ng/ml in a volume of 50 μl of MDCK cell culture 
medium and incubated with 50 μl (100 TCID50) of the infectious virus (A/Whooper Swan/Germany 
[R65-2/06]) for 1 h at 37 °C. The solution was added to MDCK cell monolayers in 96-well plates 
(Renner, Dannstadt, Germany) and incubated for three days at 37 °C in the presence of 5% CO2. After 
incubation, the cells were fixed with 3% formaldehyde and stained with naphthalene black for analysis 
under a light microscope. The neutralising titre (ND50) was determined as the mAb dilution resulting in 
50% neutralisation of infectious virus. If a neutralising effect was determined, mAbs were serially 
diluted 2-fold, starting from the mAb concentration that resulted in 100% neutralisation, and each 
dilution was tested as described above. Eight parallel cultures were infected with the virus-mAb mix. 
The ND50 was calculated according to Reed and Muench (1938). To compare the neutralisation effect 




3.1. Selection of monoclonal antibodies 
To select mAbs highly specific for the H5 antigen, a 3-step screening approach was performed: 
starting from more than 5000 hybridomas, clones that were reactive to the H5 antigen immobilised on 
a plastic surface were selected using an indirect ELISA. From the first screening round, 531 clones 
were identified that reacted with the antigen preparation. With one exception, no unspecific reactions 
to BSA, allantoic fluid, or ovalbumin were detected. In an independent second step of the screening 
process, cell-ELISA testing of hybridoma cell supernatants was used as a tool to select hybridomas 
reacting only with H5N1 virus-infected cells and to eliminate hybridomas reacting with cellular 
antigens. Non-specific reactions to cell proteins did not occur. Forty-six selected hybridoma cell culture 
supernatants were further evaluated in a third screening step performed as sandwich ELISA. There, 
21 antibodies were selected that were capable of reacting with the H5 antigen in solution. After the 
three screening procedures and after subcloning and further culturing of hybridoma cells, 11 clones 





3.2. Reactivity of mAbs 
The reactivity and specificity of the selected mAbs against AIVH5 isolates and other viruses and 
bacteria (Table 1 and Table 2) were investigated by indirect ELISAs. No cross-reactions with influenza 
B (n = 2), other respiratory viruses (n = 26), or bacteria (n = 16) were observed (data not shown). The 
reaction of the mAbs with influenza A viruses was tested with representative strains of subtype H5 
(n = 11) and the other 15 influenza A subtypes (n = 19) in three different test systems: indirect ELISA, 
sandwich assays, and western blot. Although all 11 mAbs showed strong reactivity with AIV H5 
isolates either immobilised or in solution, test result differences were observed depending on mAb, 
isolate, and method used (Table 3). In indirect ELISA, three mAbs (20/1/E6, 107/1/E4, and 140/1/D9) 
showed strong reactivity with almost all of the influenza A HA subtypes, whereas mAb 10/1/D6 
demonstrated a weak reaction against HA subtypes 1, 3, and 12. The other seven mAbs reacted 
exclusively with subtype H5 viruses. MAbs 1/03/F2 and 23/3/G5 detected all of the H5 isolates tested, 
except for the LPAIV H5N2 isolate. In the sandwich assay, where the biotinylated mAbs were applied 
as detector antibodies, fewer cross-reactivities with other influenza A subtypes were observed. Eight 
antibodies detected the subtype H5 viruses. With the exception of the broadly reacting mAb 20/1/E6, 
mAbs did not bind to any seasonal human influenza virus strain (H1N1, H3N2). Similar to the indirect 
ELISA, none of the antibodies recognised the LPAIV H5N2 strain, but several mAbs detected the 
HPAIV H5N6 isolate. 
 
3.3. Detection of isolates from different clades 
The H5N1 virus used for immunisation (A/Whooper Swan/Germany [R65-2/06]) is a German isolate 
from 2006 belonging to clade 2.2.2 (Starick et al., 2008). The results revealed that, besides clade 2.2 
(subclades 2.2.1, 2.2.2, and 2.2.3), the established mAbs – with the exception of clone 23/3/G5 – also 
recognised H5N1 clade 1 viruses (A/Hong Kong/213/03/28, A/Thailand [KAN-1]/2004). Six mAbs 
reacted with H5N1 strains isolated a year later than the immunisation virus. Remarkably, five 
antibodies detected not only the H5N1 strains circulating recently, but also the earlier AIV H5 isolate 
from 1959 (A/Chicken/Scotland/59). Nevertheless, none of the mAbs detected all nine of the HPAIV 
H5N1 isolates examined. 
 
3.4. Optimal mAb combinations 
To find mAb combinations able to detect all H5N1 isolates, extended sandwich ELISA studies were 
conducted. Selected mAbs alone or mixes of two mAbs together were used as capture and 
biotinylated detector antibodies, respectively. Finally, several pairs of mAb were identified that 
detected all nine H5N1 isolates analysed without any cross-reactions with other influenza A subtypes 
or H5N2/H5N6 viruses. One example of such a superior mAb combination is shown in Table 4. 
 
3.5. Sensitivity testing 
To evaluate the potential of selected mAb pairs to function in rapid antigen detection tests, their 
detection limit was examined in a sandwich ELISA format, which is in general the underlying principle 
of lateral flow immunochromatographic assays. An example of results are shown in Fig. 1. Using 
peroxidase-conjugated streptavidin (SA-POD) as the detection reagent, the limit of detection was 1–
10 ng/ml, depending on the concentration of the capture antibody. The use of Poly-HRP40 further 
improved the detection limit 10- to 100-fold, to 0.1–1 ng/ml, with 1 ng corresponding to 0.04–0.05 HA 
units. 
 
3.6. Western blot 
Western blot analysis was used to verify ELISA results obtained for the reactivity of mAbs and to 
identify the antigen. Ten mAbs recognised a band with a molecular weight of ∼75 kDa, corresponding 
to the HA0 protein of purified influenza virus. All of these antibodies reacted exclusively with the 
respective antigen under non-reducing conditions, suggesting that these mAbs target conformational 
epitopes. Interestingly, antibody 10/1/D6 identified a band of ∼28 kDa, corresponding to the M1 
  
protein of the virus. This mAb reacted with the antigen separated on gels under both reducing and 
non-reducing conditions, implying that mAb 10/1/D6 targets a linear epitope within the M1 protein (Fig. 
2a). To investigate the reactivity of the antibodies to other influenza A virus antigens, all 11 AIVH5 
viruses and one isolate of the H1 subtype causing most of the cross-reactions were separated under 
reducing and non-reducing conditions and probed with the different mAbs. Six mAbs reacted 
exclusively with H5 antigens, whereas five mAbs identified influenza virus H1N1 A/New 
Caledonia/20/99 as well (Table 3), indicating good correspondence with the findings obtained by 
indirect ELISA. However, in contrast to indirect ELISA results, six mAbs demonstrated a weak reaction 
with the LPAIV H5N2 isolate. 
To confirm the binding reaction of mAbs with the HA protein, the haemagglutinin was deglycosylated 
with PNGase F. Antibody 492/3/E6 and polyclonal mouse serum were used as positive controls for 
detecting the HA protein in western blot. The amount of glycosylation varies between HA proteins from 
different influenza A virus isolates. Deducing from a calculation based on the protein sequence alone, 
using a web-based application for the calculation of molecular weights and glycosylation sites from 
ExPASy (http://us.expasy.org/), it was expected that a shift of the HA0 band by ∼20 kDA for the 
respective H5 isolate would be seen. After PNGase F treatment, the molecular weight of HA0 protein 
was reduced from ∼75 kDa to ∼55 kDA, as hypothesised. This observation confirmed that mAbs 
reacted with conformational epitopes on the HA protein separated under non-reducing conditions, and 
that the binding reactions of the antibody and antigen were not affected by deglycosylation (Fig. 2b). 
 
3.7. Immunofluorescence assay for virus antigen detection 
All purified mAbs were tested for their ability to detect H5N1-infected cells by immunofluorescence 
(Table 5). Two mAbs reacted with virus-infected cells fixed in formaldehyde (A/Whooper 
Swan/Germany [R65-2/06] and A/Cygnus olor/Germany [R1349/07]), but not with H1N1- and H3N2-
infected cells. The antibody 492/3/E6 reacted poorly with infected cells, whereas mAb 22/03/D9 
showed the same specific fluorescence staining as the positive control mAb (influenza type A [pooled] 
of the WHO Influenza Reagent Kit [data not shown]). Neither antibody reacted with the uninfected 
cells. 
 
3.8. Microtitre neutralisation assay 
Two mAbs were identified that neutralised H5N1 (A/Whooper Swan/Germany [R65-2/06] mAb 1/03/F2 
and 23/3/G5) (Table 5). A concentration of 74.1 ng/ml for mAb 23/3/G5 and 33.2 ng/ml for mAb 
1/03/F2 neutralised H5N1 (100 TCID50/ml) by 50%. Further neutralisation assays with another seven 
H5N1 strains were conducted using 100 ng/ml, demonstrating that both antibodies had a broad 
neutralisation capacity against H5N1 viruses. The antibody 1/03/F2 neutralised all eight H5 strains 
tested, whereas mAb 23/3/G5 neutralised five out of eight strains (Table 6). 
 
4. Discussion 
The usefulness of rapid antigen detection tests for the diagnosis of influenza is associated with their 
predictive values and is thus highly dependent on the sensitivity and specificity of the test systems and 
the prevalence of disease in the population (Petric et al., 2006). This project was initiated because 
there was a growing demand for the improvement of commercially available test kits for diagnostics of 
H5N1 in human samples. Available rapid antigen detection systems either did not discriminate 
between influenza A virus subtypes or showed a low sensitivity, leading to such tests having 
questionable suitability for routine application in the clinical setting ( [Chan et al., 2007], [Rouleau et 
al., 2009] and [Ghebremedhin et al., 2009]). Ideally, rapid antigen detection tests would have a high 
sensitivity for detection of H5N1 virus and would also be able to differentiate between subtypes (Chan 
et al., 2007). Compared to polyclonal antibodies, mAbs offer the unique advantages of increased 
specificity, unlimited availability, and consistent properties that may be exploited for diagnostic 
applications ( [Yang et al., 2008] and [Oh et al., 2009]). 
The immunisation strategy is one of the most important steps for the generation of antibodies to detect 
native antigens. Different approaches for the immunisation of mice with influenza viruses were 
  
reported: immunisation with Bromelain-purified BHA (Russ et al., 1987), recombinant antigens ( [He et 
al., 2007] and [Yang et al., 2008]), formaldehyde-treated whole virus (Huang et al., 2007), or γ-
irradiated immunogen (Oh et al., 2009). It is known that epitopes of virus fixed in formaldehyde can be 
altered and therefore can induce mAbs, which do not react with native antigenic determinants (Duque 
et al., 1989). Beta-propiolactone (BPL)-inactivated virus was chosen for the immunisation used here 
on the basis of the following rationale: BPL preserves viruses close to their native structure and 
interacts preferentially with the viral genome (Wainberg et al., 1971) Surface proteins remain intact, 
which induces the production of mAbs against both linear and conformational epitopes. Mice that were 
immunised twice with this antigen preparation produced a long-lasting, stable titre. Furthermore, it was 
predicted that immunisation with whole virions would result in the generation of mAbs against the main 
surface protein haemagglutinin. After the fusion and application of a staged selection system, 10 of 
11 mAbs were achieved that target the HA protein, which represents about 35% of the total viral 
protein of human influenza virus (Oxford et al., 1981). Only one mAb reacted against a linear epitope 
of the viral matrix protein (M1 protein), which is associated with the inner membrane of the virion. 
Investigation of the generated mAbs revealed that the antibodies recognise distinct epitopes ranging 
from those “specific for the immunisation strain” (data not shown) to more conserved epitopes of 
influenza A viruses. No viruses or bacteria other than influenza A were recognised by the mAbs by 
indirect ELISA. The majority of the antibodies were specific for H5 strains, whereas four mAbs 
(107/1/E4, 140/1/D9, 10/1/D6, and 20/1/E6) also reacted with other influenza virus A subtypes, 
suggesting that there was binding to conserved epitopes. In a previous report using ELISA, none of 
four mAbs generated against a distinct H5N1 isolate detected H5 viruses that were isolated before the 
isolate was used for immunisation (Oh et al., 2009). It is suggested that the HA proteins of H5 viruses 
have changed significantly since the first isolation of this virus more than 30 years ago and that, 
therefore, the mAbs directed against recent H5N1 viruses do not bind to earlier H5 virus isolates. 
However, the present study revealed that three of the antibodies with a broader reaction pattern 
(20/1/E6, 107/1/E4, and 140/1/D9), as well as five H5-specific mAbs (1/03/F2, 23/3/G5, 132/03/D8, 
157/1/F4, and 492/3/E6), were able to detect recent as well as older H5 isolates (e.g., 
A/Chicken/Scotland/59). Thus, it is assumed that stable epitopes are present on the HA protein of H5 
strains, confirming observations published earlier by Varečková et al. (2008). With one exception, all of 
the antibodies detected both clade 1 and clade 2.2 H5N1 isolates, indicating that these mAbs react 
broadly with circulating H5 viruses. Western blot analysis suggested that 10 mAbs react with 
conformational HA epitopes, as they detect HA under non-reducing conditions only, whereas the one 
antibody that reacts with the M1 protein, 10/1/D6, detects a linear epitope, as it worked under reducing 
and non-reducing conditions. To verify the binding of the mAbs with the HA protein, PNGase F was 
used for deglycosylation of the haemagglutinin. The level of glycosylation of the HA protein can vary 
significantly between virus strains and can thus have a considerable impact on the molecular weight of 
the glycoprotein (Harvey et al., 2008). Previous reports have shown the altered migration 
characteristics for deglycosylated HA1/HA2 proteins after denaturation and under reducing conditions 
( [Harvey et al., 2008] and [Li et al., 2010]). As expected, enzyme treatment resulted in a smaller-
sized, faster-migrating HA protein, and a band shift from ∼75 kDa to ∼55 kDa was demonstrated, 
confirming that the generated mAbs detected exclusively the protein backbone of the HA molecule. 
Furthermore, it has been determined that the ectodomain of the HA protein undergoes conformational 
changes when the virus preparation is treated with temperatures ≥63 °C (Epand and Epand, 2002). 
This could explain the finding that the mAbs did not react with the HA protein after an incubation at 
100 °C under reducing conditions. 
The HA protein of influenza virus is the target of neutralising antibodies. Former studies described five 
distinct neutralisation epitopes for H5N9 on the HA protein (Philpott et al., 1989). Recombinant human 
antibodies against influenza A H5N1 viruses described recently showed a 50% neutralisation effect 
against 100 TICD50 H5 viruses at antibody concentrations between 0.2 μg/ml and >500 μg/ml, 
depending on the clade of H5N1 (Sun et al., 2009). However, two antibodies (1/03/F2 and 23/3/G5) 
were able to protect MDCK cells against H5N1 infection. Treatment of H5N1 viruses with antibody 
concentrations of 33 ng/ml and 75 ng/ml, respectively, resulted in a 50% neutralisation of the 
immunisation strain of H5N1. Neutralisation was not only observed for the virus used for immunisation, 
but also for other H5N1 isolates tested. The antibody 1/03/F2 neutralised viruses from H5N1 clades 1 
and 2, whereas the antibody 23/3/G5 reacted only with viruses from H5N1 clade 2. Whether or not 
such antibodies could be used as source for the production of therapeutic antibodies has yet to be 
seen. 
  
The purpose of the present investigation was to develop mAbs which could be used for the 
development of antigen detection systems. Therefore, the mAbs were used in a sandwich ELISA, 
either as capture or detector antibodies. Eight mAbs were shown to react specifically with the non-
immobilised H5 antigen, which is important for their application in the sandwich-based lateral flow 
assays. In general, there was a good correlation regarding antibody specificity between the three 
immunological assay systems used. Differences in epitope recognition must be expected because 
availability of the antigenic sites is probably dependent on the test system used. It has long been 
known that antigen conformation on a solid phase appears to be different from one in solution (Vaidya 
et al., 1985). On the one hand, a portion of injected material may have changed its conformation, 
which exposed immunogenic sites that are hidden on the native protein. On the other hand, there are 
sites which are exposed on the native protein but are masked when the antigen is adsorbed onto 
plastic surfaces and vice versa (Mierendorf and Dimond, 1983). While these are only conformational 
changes, in western blotting, the denaturation of proteins will lead to changes in antigen presentation 
and epitope accessibility, thereby affecting antigen–antibody interaction. 
Several H5-specific antibodies were generated that are able to recognise recently circulating and older 
H5 viruses, both immobilised and in solution. However, one mAb alone was not enough to detect all 
nine H5N1 isolates examined. To achieve this aim, different combinations of mAbs were evaluated 
using sandwich ELISA. Several mAb pairs were identified that detected all H5N1 viruses analysed, 
without any cross-reactions with other influenza viruses. This was of great significance for the intended 
application of generated mAbs in an H5N1-specific rapid antigen detection system. Moreover, 
established combinations of mAbs resulted in higher absorbance readings for some H5 viruses, 
suggesting that combined mAbs were directed to different epitopes on the virus particles. These 
findings are in agreement with previous studies and have confirmed that mAb combinations can be 
used to increase ELISA sensitivity (He et al., 2007). 
The present study demonstrated the ability of mAbs to detect low antigen concentrations, which 
makes them appropriate for developing enhanced rapid antigen detection systems. According to their 
instruction leaflets, available tests generally have a sensitivity of ≥1 HA (WHO, 2005). Importantly, the 
results of the established sandwich ELISA showed that the detection limit for H5N1 virus can be 
improved to 0.04–0.05 HA (1 ng/ml), indicating the potential for increasing the sensitivity of rapid 
antigen detection tests. Furthermore, when using Poly-HRP40 conjugate instead of HRP-conjugated 
streptavidin, the detection limit was significantly improved, to 0.004–0.005 HA (0.1 ng/ml). Based on 
these results, it is expected that the application of the newly generated mAbs in rapid antigen 
detection tests using Poly-HRP40 conjugate would result in a 25- to 250-fold higher sensitivity of such 
an assay in comparison with the ones currently available. Prospective studies should be performed to 
test the generated antibodies with clinical samples to verify whether the sensitivity of the test systems 
might be influenced by sample matrices or by poor quality of the sample. Samples that are not 
collected appropriately may contain smaller amounts of virus and, thus, are associated with a lower 
sensitivity. The type of transport media is also important, as some of its components may influence the 
sensitivity of the test. In addition, a dilution of swabs for additional laboratory tests may also lead to 
negative rapid test results. Therefore, the authors suggest using at least one nasal swab, undiluted, 
directly for screening and a second swab (nasal or/and throat swab) in transport medium for further 
investigations, such as PCR or virus culture. 
Regarding the H1N1 pandemic starting in 2009, the need for rapid antigen detection tests with reliable 
results remains essential. Such systems are useful in clinical settings where fast assays guide 
physicians to make the best possible clinical decisions, for example, when a quarantine of infected 
patients is needed, followed by clinical and therapeutic monitoring. Next to the clinical application, the 
use of rapid antigen detection tests is desirable for community surveillance, in facility outbreaks and 
other epidemiological situations, in order to detect epidemiological trends (Rouleau et al., 2009).The 
discussion of rapid antigen detection systems mainly involves sensitivity and specificity. A recent 
evaluation of several test methods for the detection of the novel 2009 influenza A (H1N1) confirm that 
both criteria remain questionable ( [Ginocchio et al., 2009], [Vasoo et al., 2009] and [Sambol et al., 
2010]). The problems of sensitivity and specificity in rapid antigen detection systems remain, whether 
H5N1 or pandemic H1N1 viruses are present, and therefore, the need for better assays is essential. 
So far, the World Health Organization does not recommend the routine use of rapid tests alone for 
surveillance purposes or patient management without confirmatory testing ( [WHO, 2005], [WHO, 
2007] and [WHO, 2009]). 
  
This paper describes the generation of highly specific mAbs against H5 viruses, which might be a 
useful tool for the development of rapid diagnostic systems. The mAbs produced can now be applied 
in a variety of immunoassays for point-of-care tests of AI infections. Based on the ELISA results, some 
of the newly produced mAbs and mAb combinations established are appropriate to improve available 
rapid antigen detection systems for the diagnosis of H5N1 infections in the areas of both specificity 
and sensitivity. Studies are under way to implement the novel antibodies in different test platforms. 
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Table 3. Evaluation of the specificity of mAbs against Influenza A viruses by indirect ELISA 




Given are the number of virus isolates detected by the mAb and the number of viruses tested, 
respectively. mAb = monoclonal antibody. 
a
 Capture Ab = rabbit anti-H5N1 polyclonal antibody, detector Ab = biotinylated mAb. 
b
 See Table 1. 
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Numbers indicate the number of virus isolates detected by the mAb and the number of viruses tested, 
respectively. mAb = monoclonal antibody; pAb H5N1: rabbit anti-H5N1 polyclonal antibody. 
 
 
Table 5. Characterisation of mAbs raised against inactivated H5N1 virus A/Whooper Swan/Germany 





 The heavy chain was not definitely determinable. 
 
Table 6. Neutralisation capacity of mAb 1/03/F2 and mAb 23/3/G5 with different H5N1 strains. 
 
 
+++: 3/3 wells without CPE; ++: 2/3 wells without CPE; +: 1/3 wells without CPE; −: 3/3 wells with 
CPE. 
  
Figure 1. ELISA: Determination of detection limit (LoD) for H5N1, A/Whooper Swan/Germany (R65-
2/06) used for immunisation. Capture mAb was coated to the wells in concentrations of 0.5, 1.0, or 
5.0 μg/ml. SA-POD: peroxidase-conjugated streptavidin; Poly-HRP: peroxidase-conjugated 




Figure 2. Western blot analysis of selected mAbs and H5N1 A/Whooper Swan/Germany (R65-2/06). 
(a) Western blot analysis was performed with H5N1 A/Whooper Swan/Germany (R65-2/06). The blots 
are representative of all 11 mAbs presented here. 107/1/E4 reacted with influenza HA protein 
(∼77 kDa) of subtypes H5 and H1, 10/1/D6 bound to M1 protein (28 kDa), and 492/3/E6 detected H5 
HA exclusively. (b) Western blot analysis with deglycosylated HA-protein of H5N1, A/Whooper 
Swan/Germany (R65-2/06), using mAb 492/3/E6 and polyclonal mouse serum (control) as primary 
antibodies. 
